Phenotypes associated with this allele

• Allele Symbol: Aicda⁺
• Allele Name: wild type
• Allele ID: MGI:2435753
• Summary: 10 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
ht1	Aicda^tm1.1(cre/ERT2)Crey/Aicda^+	involves: 129P2/OlaHsd * C57BL/6	MGI:4442998
ht2	Aicda^tm1Hon/Aicda^+	involves: C57BL/6 * CBA	MGI:3809683
ht3	Aicda^tm3Mnz/Aicda^+	involves: C57BL/6 * CBA	MGI:3818478
ht4	Aicda^tm4Mnz/Aicda^+	involves: C57BL/6 * CBA	MGI:3818479
cn5	Aicda^tm1(cre)Mnz/Aicda^+ Gt(ROSA)26Sor^tm2(sb11)Njen/Gt(ROSA)26Sor^+ TgTn(sb-T2/Onc2)6070Njen/0	involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J	MGI:4367198
cn6	Dicer1^tm1Bdh/Dicer1^tm1Bdh Aicda^tm1(cre)Njen/Aicda^+	involves: 129 * C57BL/6	MGI:5315120
cn7	Igh^tm1Mnz/Igh^tm1Mnz Dis3^tm1.1Uba/Dis3^tm1.1Uba Aicda^tm1(cre)Uba/Aicda^+	involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6	MGI:6695985
cn8	Aicda^tm1(cre)Mnz/Aicda^+ Igh^tm3Mnz/Igh^+ Myc^tm37Mnz/Myc^+	involves: 129P2/OlaHsd * C57BL/6	MGI:3836397
cn9	Aicda^tm1(cre)Mnz/Aicda^+ Igh^tm3Mnz/Igh^+ Myc^tm39Mnz/Myc^+	involves: 129P2/OlaHsd * C57BL/6	MGI:3836396
cn10	Bcl2l11^tm1Ast/Bcl2l11^tm1Ast Dicer1^tm1Bdh/Dicer1^tm1Bdh Aicda^tm1(cre)Njen/Aicda^+	involves: 129S1/Sv * C57BL/6	MGI:5315121

Genotype
MGI:4442998

ht1

• Allelic Composition: Aicda^{tm1.1(cre/ERT2)Crey}/Aicda⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

normal phenotype

no abnormal phenotype detected ( J:157741 )

• mice are viable and fertile; no details of analysis are available

Genotype
MGI:3809683

ht2

• Allelic Composition: Aicda^tm1Hon/Aicda⁺
• Genetic Background: involves: C57BL/6 * CBA

immune system

immune system phenotype ( J:136224 )

N • mice exhibit normal somatic hypermutation rates

abnormal class switch recombination ( J:136224 , J:141427 )

• class switching is impaired compared to in wild-type mice (J:136224)

• B cells show 80% the level of class switch recombination (CSR) to IgG1 that occurs with wild-type controls when cultured in the presence of LPS and IL-4 (J:141427)

abnormal somatic hypermutation frequency ( J:141427 )

• somatic hypermutation by germinal center B cells is 75% of what occurs in wild-type

• somatic hypermutation by Peyer's patch B cells is 40% of what occurs in wild-type

hematopoietic system

abnormal class switch recombination ( J:136224 , J:141427 )

• class switching is impaired compared to in wild-type mice (J:136224)

• B cells show 80% the level of class switch recombination (CSR) to IgG1 that occurs with wild-type controls when cultured in the presence of LPS and IL-4 (J:141427)

abnormal somatic hypermutation frequency ( J:141427 )

• somatic hypermutation by germinal center B cells is 75% of what occurs in wild-type

• somatic hypermutation by Peyer's patch B cells is 40% of what occurs in wild-type

Genotype
MGI:3818478

ht3

• Allelic Composition: Aicda^tm3Mnz/Aicda⁺
• Genetic Background: involves: C57BL/6 * CBA

immune system

abnormal class switch recombination ( J:141427 )

• B cells show 32% the level of class switch recombination (CSR) to IgG1 that occurs with wild-type controls when cultured in the presence of LPS and IL-4

• when stimulated with LPS or LPS and anti-dextran, B cells show 19 or 16% the level of CSR to IgG3 of wild-type controls

abnormal somatic hypermutation frequency ( J:141427 )

• somatic hypermutation by germinal center B cells is 30% of what occurs in wild-type

• somatic hypermutation by Peyer's patch B cells is 20% of what occurs in wild-type

hematopoietic system

abnormal class switch recombination ( J:141427 )

• B cells show 32% the level of class switch recombination (CSR) to IgG1 that occurs with wild-type controls when cultured in the presence of LPS and IL-4

• when stimulated with LPS or LPS and anti-dextran, B cells show 19 or 16% the level of CSR to IgG3 of wild-type controls

abnormal somatic hypermutation frequency ( J:141427 )

• somatic hypermutation by germinal center B cells is 30% of what occurs in wild-type

• somatic hypermutation by Peyer's patch B cells is 20% of what occurs in wild-type

Genotype
MGI:3818479

ht4

• Allelic Composition: Aicda^tm4Mnz/Aicda⁺
• Genetic Background: involves: C57BL/6 * CBA

immune system

abnormal class switch recombination ( J:141427 )

• B cells show 87% the level of class switch recombination (CSR) to IgG1 that occurs with wild-type controls when cultured in the presence of LPS and IL-4

• when stimulated with LPS or LPS and anti-dextran, B cells show 71 or 52% the level of CSR to IgG3 of wild-type controls

abnormal somatic hypermutation frequency ( J:141427 )

• somatic hypermutation by germinal center B cells is 45% of what occurs in wild-type

• somatic hypermutation by peyer's patch B cells is 40% of what occurs in wild-type

hematopoietic system

abnormal class switch recombination ( J:141427 )

• B cells show 87% the level of class switch recombination (CSR) to IgG1 that occurs with wild-type controls when cultured in the presence of LPS and IL-4

• when stimulated with LPS or LPS and anti-dextran, B cells show 71 or 52% the level of CSR to IgG3 of wild-type controls

abnormal somatic hypermutation frequency ( J:141427 )

• somatic hypermutation by germinal center B cells is 45% of what occurs in wild-type

• somatic hypermutation by peyer's patch B cells is 40% of what occurs in wild-type

Genotype
MGI:4367198

cn5

• Allelic Composition: Aicda^tm1(cre)Mnz/Aicda⁺; Gt(ROSA)26Sor^{tm2(sb11)Njen}/Gt(ROSA)26Sor⁺; TgTn(sb-T2/Onc2)6070Njen/0
• Genetic Background: involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J

mortality/aging

premature death ( J:153656 )

• compared with Gt(ROSA)26Sor^{tm2(sb11)Njen} TgTn(sb-T2/Onc2)6070Njen mice

neoplasm

increased tumor incidence ( J:153656 )

• greater than 90% of moribund mice develop tumors with an average latency of 46 weeks

increased skin squamous cell carcinoma incidence ( J:153656 )

• in one mouse

increased medulloblastoma incidence ( J:153656 )

• in one mouse

increased hemolymphoid system tumor incidence ( J:153656 )

• mice develop hematopoietic tumors including B cell, T cell, and myeloid tumors unlike Gt(ROSA)26Sor^{tm2(sb11)Njen} TgTn(sb-T2/Onc2)6070Njen mice that do not develop tumors

increased T cell derived lymphoma incidence ( J:153656 )

• 3 T cell lymphomas develop

increased leukemia incidence ( J:153656 )

• 2 myeloid leukemia tumors develop

increased B cell derived lymphoma incidence ( J:153656 )

• mice develop B cell lymphomas including diffuse large cell lymphomas and follicular lymphomas

• one mouse developed pre-B lymphoma

increased follicular lymphoma incidence ( J:153656 )

integument

increased skin squamous cell carcinoma incidence ( J:153656 )

• in one mouse

nervous system

increased medulloblastoma incidence ( J:153656 )

• in one mouse

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:153656 )

• 3 T cell lymphomas develop

immune system

increased T cell derived lymphoma incidence ( J:153656 )

• 3 T cell lymphomas develop

hematopoietic system

increased T cell derived lymphoma incidence ( J:153656 )

• 3 T cell lymphomas develop

Genotype
MGI:5315120

cn6

• Allelic Composition: Dicer1^tm1Bdh/Dicer1^tm1Bdh; Aicda^tm1(cre)Njen/Aicda⁺
• Genetic Background: involves: 129 * C57BL/6

immune system

immune system phenotype ( J:181782 )

N • before immunization, mice have normal B-cell subsets in the bone marrow, spleen, lymph nodes, and peritoneal cavities

decreased germinal center B cell number ( J:181782 )

• significantly decreased numbers (6- to 10 fold) of germinal center (GC) B cells are present in the spleen at day 10 after immunization

• drastic reductions in GC B cell populations in Peyer patches and mesenteric lymph nodes are also observed

absent memory B cells ( J:181782 )

• NP-specific memory B (IgG1) cells are essentially absent from spleens of mice 56 days after primary immunization with NP-CGG

absent plasma cells ( J:181782 )

• NP-specific IgG1 antibody-secreting cells (ASCs) are absent from the bone marrow at 56 days after primary immunization with NP-CGG

abnormal germinal center B cell physiology ( J:181782 )

• at 10 days after immunization, numbers of proliferating GC B cells are 3- to 5-fold lower than in wild-type, suggesting impaired proliferative capacity

• GC B cells are mores susceptible to cell death; numbers of apoptotic cells are 30 to 50% higher than in controls at day 10 after immunization

abnormal humoral immune response ( J:181782 )

• upon immunization with a T cell dependent antigen (NP-CGG), mice display normal levels of NP-specific IgM antibodies at 14, 21, and 28 days following exposure, while NP-specific IgG1, IgGb and IgG3 antibody titers are drastically reduced

decreased immunoglobulin level ( J:181782 )

• mice have lower basal serum levels of IgG1, IgG2b, IgG3, and IgA compared to wild-type

• IgM level is normal

hematopoietic system

decreased germinal center B cell number ( J:181782 )

• significantly decreased numbers (6- to 10 fold) of germinal center (GC) B cells are present in the spleen at day 10 after immunization

• drastic reductions in GC B cell populations in Peyer patches and mesenteric lymph nodes are also observed

absent memory B cells ( J:181782 )

• NP-specific memory B (IgG1) cells are essentially absent from spleens of mice 56 days after primary immunization with NP-CGG

absent plasma cells ( J:181782 )

• NP-specific IgG1 antibody-secreting cells (ASCs) are absent from the bone marrow at 56 days after primary immunization with NP-CGG

abnormal germinal center B cell physiology ( J:181782 )

• at 10 days after immunization, numbers of proliferating GC B cells are 3- to 5-fold lower than in wild-type, suggesting impaired proliferative capacity

• GC B cells are mores susceptible to cell death; numbers of apoptotic cells are 30 to 50% higher than in controls at day 10 after immunization

decreased immunoglobulin level ( J:181782 )

• mice have lower basal serum levels of IgG1, IgG2b, IgG3, and IgA compared to wild-type

• IgM level is normal

Genotype
MGI:6695985

cn7

• Allelic Composition: Igh^tm1Mnz/Igh^tm1Mnz; Dis3^tm1.1Uba/Dis3^tm1.1Uba; Aicda^tm1(cre)Uba/Aicda⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6

immune system

abnormal somatic hypermutation frequency ( J:302856 )

• mice immunized to induced somatic hypermutation show higher mutation frequencies in germinal center derived B cells

• the C to T mutation frequency is increased and inversely, the G to A mutation frequency is decreased in germinal cell B cells, indicating dysregulation of activation-induced cytidine deaminase activity at the V(D)J exon during somatic hypermutation

hematopoietic system

abnormal somatic hypermutation frequency ( J:302856 )

• mice immunized to induced somatic hypermutation show higher mutation frequencies in germinal center derived B cells

• the C to T mutation frequency is increased and inversely, the G to A mutation frequency is decreased in germinal cell B cells, indicating dysregulation of activation-induced cytidine deaminase activity at the V(D)J exon during somatic hypermutation

Genotype
MGI:3836397

cn8

• Allelic Composition: Aicda^tm1(cre)Mnz/Aicda⁺; Igh^tm3Mnz/Igh⁺; Myc^tm37Mnz/Myc⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

cellular

spontaneous chromosome breakage ( J:145691 )

• B cells within in Peyer's Patches or splenic B cells stimulated in vitro can have chromosomal translocations involving chromosomes 12 and 15

• the chromosome fusions occur precisely at the two loxP sites that exist in the Igh and Myc mutant alleles

immune system

abnormal B cell physiology ( J:145691 )

• B cells within in Peyer's Patches or splenic B cells stimulated in vitro can have chromosomal translocations involving chromosomes 12 and 15

• the chromosome fusions occur precisely at the two loxP sites that exist in the Igh and Myc mutant alleles

hematopoietic system

abnormal B cell physiology ( J:145691 )

• B cells within in Peyer's Patches or splenic B cells stimulated in vitro can have chromosomal translocations involving chromosomes 12 and 15

• the chromosome fusions occur precisely at the two loxP sites that exist in the Igh and Myc mutant alleles

Genotype
MGI:3836396

cn9

• Allelic Composition: Aicda^tm1(cre)Mnz/Aicda⁺; Igh^tm3Mnz/Igh⁺; Myc^tm39Mnz/Myc⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

cellular

spontaneous chromosome breakage ( J:145691 )

• B cells within in Peyer's Patches or splenic B cells stimulated in vitro can have chromosomal translocations involving chromosomes 12 and 15

• the chromosome fusions occur precisely at the two loxP sites that exist in the Igh and Myc mutant alleles

immune system

abnormal B cell physiology ( J:145691 )

• B cells within in Peyer's Patches or splenic B cells stimulated in vitro can have chromosomal translocations involving chromosomes 12 and 15

• the chromosome fusions occur precisely at the two loxP sites that exist in the Igh and Myc mutant alleles

hematopoietic system

abnormal B cell physiology ( J:145691 )

• B cells within in Peyer's Patches or splenic B cells stimulated in vitro can have chromosomal translocations involving chromosomes 12 and 15

• the chromosome fusions occur precisely at the two loxP sites that exist in the Igh and Myc mutant alleles

Genotype
MGI:5315121

cn10

• Allelic Composition: Bcl2l11^tm1Ast/Bcl2l11^tm1Ast; Dicer1^tm1Bdh/Dicer1^tm1Bdh; Aicda^tm1(cre)Njen/Aicda⁺
• Genetic Background: involves: 129S1/Sv * C57BL/6

immune system

abnormal B cell differentiation ( J:181782 )

• rescued germinal center B cells cannot effectively differentiate into antibody-secreting cells (AScs), and fail to differentiate into high affinity ASCs

decreased germinal center B cell number ( J:181782 )

• numbers are reduced in spleen relative to wild-type, but are dramatically increased on a Bcl2l11-deficient background compared to conditional knockouts with wild-type background

decreased plasma cell number ( J:181782 )

• NP-specific IgG1 antibody-secreting cells (ASCs) are present only at 20-25% of the numbers observed in wild-type spleens at day 12 after immunization

• high affinity ASCs are almost undetectable and bone marrow

hematopoietic system

abnormal B cell differentiation ( J:181782 )

• rescued germinal center B cells cannot effectively differentiate into antibody-secreting cells (AScs), and fail to differentiate into high affinity ASCs

decreased germinal center B cell number ( J:181782 )

• numbers are reduced in spleen relative to wild-type, but are dramatically increased on a Bcl2l11-deficient background compared to conditional knockouts with wild-type background

decreased plasma cell number ( J:181782 )

• NP-specific IgG1 antibody-secreting cells (ASCs) are present only at 20-25% of the numbers observed in wild-type spleens at day 12 after immunization

• high affinity ASCs are almost undetectable and bone marrow